Premium
Therapy refractory angioimmunoblastic T‐cell lymphoma in complete remission with lenalidomide
Author(s) -
Beckers Mariëlle M.,
Huls Gerwin
Publication year - 2013
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12053
Subject(s) - lenalidomide , angioimmunoblastic t cell lymphoma , refractory (planetary science) , prednisone , medicine , lymphoma , oncology , gastroenterology , dermatology , multiple myeloma , immunology , materials science , t cell , immune system , composite material
The prognosis of therapy refractory angioimmunoblastic lymphoma ( AITL ) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow‐up, the patient has no detectable disease. Lenalidomide was well tolerated without side‐effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL .